Advertisement

Topics

Tricida, Inc. Company Profile

10:08 EDT 22nd October 2018 | BioPortfolio

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully completed a pivotal Phase 3, double-blind, placebo-controlled trial of TRC101 in CKD patients with metabolic acidosis. The results of this Phase 3 trial, along with results from a successful double-blind, randomized, placebo-controlled Phase 1/2 trial and an ongoing safety extension trial, TRCA-301E, are intended to serve as the basis for the submission of an NDA for TRC101 under the FDA’s Accelerated Approval Program.


News Articles [23 Associated News Articles listed on BioPortfolio]

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Wednesday, August 8, 2018

Tricida, Inc. (NASDAQ: TCDA) today announced that it will report its second quarter 2018 financial results after the close of market on Wednesday, August 8, 2018. Tricida will h...

Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results For TRC101

NewsTRC101 represents a first-in-class candidate for the treatment of metabolic acidosis, a common complication of CKD that can accelerate progression of kidney disease, increase the risk of muscle wa...

Tricida Files $150M IPO, Shares Kidney Drug Trial Results

Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $15...

Tricida's initial public offering nets $206.7mm

Renal disease drug developer Tricida Inc. netted $206.7mm through its initial public offering of 11.7mm common shares at $19. (The company initially planned to sell 10.3mm shares at a range of $16-18....

Deals this week: Deciphera Pharmaceuticals, Tricida, ENYO Pharma

Deciphera Pharmaceuticals has raised $97.16m through an underwritten public offering of 3.75 million shares of its common stock. The underwriters...Read More... The post Deals this week: Deciphera Pha...

Tricida enters $100mm loan agreement with Hercules; gets $25mm up front

Tricida Inc. entered a $100mm venture debt agreement with Hercules Capital. The company drew down an initial $25mm up front, with anther $50mm available subject to the achievement of certain milestone...

Tricida files for $150M IPO

Tricida Prepares For $175 Million U.S. IPO

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Tricida, Inc.

Tricida, Inc., is a pre-clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics. Tricida’s lead program is TRC101, a ...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acido...

More Information about "Tricida, Inc." on BioPortfolio

We have published hundreds of Tricida, Inc. news stories on BioPortfolio along with dozens of Tricida, Inc. Clinical Trials and PubMed Articles about Tricida, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tricida, Inc. Companies in our database. You can also find out about relevant Tricida, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record